Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain Directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan.
Share Options were granted as follows:
| Name | Number of Share Options granted | Total no. of ordinary shares under option post grant | % of existing issued share capital | Effective Grant date |
| Peter Keeling, CEO | 73,542 | 253,542 | 0.30% | 1 April 2021 |
| Philip White, CFO | 64,154 | 244,154 | 0.29% | 1 April 2021 |
| Ryan Keeling, CIO | 64,154 | 244,154 | 0.29% | 1 April 2021 |
| Damian Thornton, COO and PDMR | 64,062 | 166,766 | 0.20% | 1 April 2021 |
| Jordan Clark, CCO and PDMR | 46,003 | 122,117 | 0.15% | 1 April 2021 |
| Susanne Munksted, PDMR | 45,475 | 116,147 | 0.14% | 1 April 2021 |
| Other employees (36 persons) | 534,581 | 869,811 | 1.03% | 1 April 2021 |
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, measured using the average mid-market closing share price in the month immediately before the end of the Performance Period, plus any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 102.67p, being the average mid-market closing share price in the three days prior to 1 April 2021, when the options were issued. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.
Following this grant, the total number of share options outstanding in the Company is 2,016,687, representing approximately 2.4% of its current issued share capital of 84,063,923.
Enquiries:
| Diaceutics PLC | |||
| Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
| Philip White, Chief Financial Officer |
| ||
|
|
| ||
| Cenkos Securities plc (Nominated adviser and broker) | +44 (0)207 397 8900 | ||
| Callum Davidson / Giles Balleny |
| ||
| Michael Johnson (Sales) |
| ||
|
|
| ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com | ||
| Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
| Paul McManus | Mob: +44 (0)7980 541 893 | ||
|
|
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - the Diagnostic Network ® provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform. www.diaceutics.com
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Peter Keeling | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Executive Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| Exercise price of £0.002 per share | 73,542 |
| |||||
|
| |||||||
| e. | Date of the transaction | 1 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Philip White | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Financial Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| Exercise price of £0.002 per share | 64,154 |
| |||||
|
| |||||||
| e. | Date of the transaction | 1 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Ryan Keeling | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Innovation Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| Exercise price of £0.002 per share | 64,154 |
| |||||
|
| |||||||
| e. | Date of the transaction | 1 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Damian Thornton | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Operating Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| Exercise price of £0.002 per share | 64,062 |
| |||||
|
| |||||||
| e. | Date of the transaction | 1 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Jordan Clark | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Chief Technology Officer | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| Exercise price of £0.002 per share | 46,003 |
| |||||
|
| |||||||
| e. | Date of the transaction | 1 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a. | Name | Susanne Munksted | |||||
| 2 | Reason for notification |
| |||||
| a. | Position/Status | Managing Director and PDMR | |||||
| b. | Initial notification/ Amendment | Initial | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a. | Name | Diaceutics PLC | |||||
| b. | LEI | 213800VEWQBB39ZB8J81 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a. | Description of the financial instrument, type of instrument | Options over new ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
| b. | Nature of the transaction | Grant of share options | |||||
| c. | Price(s) and volume(s) |
|
|
|
|
| |
|
| Price(s) | Volume(s) |
| ||||
| Exercise price of £0.002 per share | 45,475 |
| |||||
|
| |||||||
| e. | Date of the transaction | 1 April 2021 | |||||
| f. | Place of the transaction | Outside a trading venue | |||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
